WeMed Medical Was Awarded As The Biotechnology Innovation 50 Enterprise By KPMG China

WeMed Medical, as a representative of national high-end medical enterprises, has always been adhering to the vision of "Innovation For Health". In June 2022, the first KPMG China Biotechnology Innovation 50 Enterprises was grandly announced, and WeMed Medical was honored to receive this honor.

Mr. Yang He, CEO of WeMed Medical, was invited to attend the meeting and gave a speech. At the meeting, he clarified the important role of WeMed Medical in the development of biotechnology, and also expressed his views and hopes for the development prospects of the field of biotechnology.

WeMed Medical focuses on the field of interventional medicine, drives development with technological innovation, and has achieved many scientific research achievements.

At the same time, WeMed Medical has created a full range of interventional diagnosis and treatment equipment such as DSA system, Mobile C arm X ray Machine, Mobile C arm X ray Compact, Interventional Robot,  and solutions in practice, providing safer and more efficient surgical methods, and is committed to solving clinical pain points for both doctors and patients, and protecting life and health with practical actions.

Biotechnology is a golden track for flourishing development, where health is linked, and life is supported. In the future, WeMed Medical expects to work with various excellent biotechnology companies to escort life with technological innovation.

The first KPMG China Biotechnology Innovation 50 Enterprise Selection Event was launched in August 2021, and received strong support and attention from experts and representatives from scientific research, industry, investment, enterprises and other fields. According to the five core selection dimensions, more than ten authoritative experts were invited to serve as judges. The companies were evaluated from six fields of biopharmaceuticals, cell therapy, gene therapy, in-vitro diagnostics, medical devices, and drug R&D, select potential biotechnology innovation companies, link more resources for them, and work with many parties in the ecosystem to jointly promote the high-quality and healthy development of China's biotech innovation industry.